Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 756 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma
Interventions: Latanoprost (0.005%); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Open-Angle, Eye Diseases
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: EyeCheck, Traditional Tonometer (Goldmann and Tonopen); Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 21
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 18 more

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dothan, Alabama

Conditions: Normal Tension Glaucoma
Interventions: Netarsudil, Brimonidine; Drug
Lead sponsor: Westlake Eye Specialists; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Austin, Texas • Killeen, Texas • Kyle, Texas + 1 more

Conditions: Open Angle Glaucoma -Ocular Hypertension
Interventions: Latanoprost, SAR366234; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Inglewood, California • Cape Coral, Florida • Roswell, Georgia + 2 more

Conditions: Glaucoma
Interventions: 0.005% Latanoprost dosed once.; Drug
Lead sponsor: Nanduri, Padma, M.D., FACS; Individual
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Visalia, California

Conditions: Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension
Interventions: Selective Laser Trabeculoplasty; Device
Lead sponsor: Northeastern State University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tahlequah, Oklahoma

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic; Drug
Lead sponsor: Altheos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 5
States / cities: Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more

Conditions: Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions: dorzolamide/timolol; Drug
Lead sponsor: CT Glaucoma Associates; Other
Eligibility: 25 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glendale, Arizona

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: KDB/Phacoemulsification, Trabectome/Phacoemulsification; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 95 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Glaucoma
Interventions: MEMS cap; Device
Lead sponsor: Robin, Alan L., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: OPA-6566, Placebo, Latanoprost; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Artesia, California • Glendale, California • Roswell, Georgia + 6 more

Conditions: Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions: Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®); Drug
Lead sponsor: YS Life Science Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Ocular Hypertension
Interventions: Sensimed Triggersfish® (TF); Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glaucoma
Interventions: Triesence, balanced salt solution BSS; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Eye Disease, Eye Care
Interventions: tailored newsletter, targeted newsletter; Behavioral
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 65 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Photobionic IOP Tonometer (PIB); Device
Lead sponsor: EyeCBetter Corporation; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: La Quinta, California

Conditions: Open Angle Glaucoma
Interventions: Hydrus Microstent; Device
Lead sponsor: InSight Vision Center Medical Group, Inc; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fresno, California

Search by objective public record fields.

Optic Nerve Head Strain in Non-glaucoma Subjects

The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study

Reliability and Reproducibility of the Eye Check Tonometer

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

Adjunctive Study of AL-37807 Ophthalmic Suspension

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

Observational Study of How Patients Take Eye Drops

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Tracking Optical Coherence Tomography

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

Tailored Messages to Increase Eye Examination Behavior

Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor Tonometer

Hydrus Microstent as a Quality of Life Consideration